systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-487Research ArticleКАРДИОНЕВРОЛОГИЯВыбор антигипертензивной терапии для коррекции когнитивных нарушений и профилактики деменции: возможности валсартана и его фиксированной комбинации с гидрохлоротиазидомThe choice of antihypertensive therapy in correction of cognitive impairments and prevention of dementia: possibilities of valsartan and fixed-dose combination of valsartan and hydrochlorothiazideОстроумоваО. Д.OstroumovaO. D.ostroumova.olga@mail.ruГареликИ. А.GarelikI. A.2sinochka@mail.ruКаравашкинаЕ. А.KaravashkinaE. A.karall2007@rambler.ruФГБОУ ВО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России; ФГБОУ ВО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава РоссииРоссияA.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation; I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationRussian FederationФГБОУ ВО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РоссииРоссияA.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian FederationRussian Federation2016231220221344755Copyright © Остроумова О.Д., Гарелик И.А., Каравашкина Е.А., 20222022Остроумова О.Д., Гарелик И.А., Каравашкина Е.А.Ostroumova O.D., Garelik I.A., Karavashkina E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/487

В статье приведены определение, классификация и патогенетические механизмы нарушения когнитивных функций при артериальной гипертонии. Обсуждаются возможности антигипертензивных препаратов разных классов в коррекции когнитивных нарушений и профилактике деменции. Рассмотрены преимущества блокаторов рецепторов к ангиотензину II в профилактике деменции и их потенциальные механизмы церебропротекции. Подробно описаны возможности валсартана в коррекции когнитивных нарушений при артериальной гипертонии, его преимущества перед другими блокаторами ренин-ангиотензин-альдостероновой системы и его уникальные нейропротективные механизмы. Приведены результаты собственного исследования фиксированной комбинации валсартан/гидрохлоротиазид, в котором выявлены ее высокая антигипертензивая и церебропротективная (способность улучшать когнитивные функции) эффективность.

This article discusses the definition, classification and pathogenetic mechanisms of cognitive functions in arterial hypertension. The authors discuss the capabilities of the different classes of antihypertensive drugs in correction of cognitive impairments and prevention of dementia. The authors also discuss the advantages of the angiotensin II receptor blockers in prevention of dementia and in their potential mechanisms of cerebral protection. The article describes in detail the possibilities of valsartan in correction of cognitive impairments associated with arterial hypertension, the advantages of valsartan in comparison with calcium antagonists and its unique neuroprotective mechanisms. We show our own results of the study concerning fixed-dose combination of valsartan and hydrochlorothiazide, and find out that this combination has high antihypertensive and cerebral protection (capacity to improve cognitive function) and effectiveness.

артериальная гипертониякогнитивные функциидеменцияантигипертензивная терапияантагонисты рецепторов к ангиотензину IIвалсартангидрохлоротиазидфиксированные комбинации антигипертензивных препаратовarterial hypertensioncognitive functionsdementiaantihypertensive therapyangiotensin II receptor antagonistsvalsartanhydrochlorothiazidefixed-dose combinations of antihypertensive drugsReferencesЗахаров В.В., Локшина А.Б. Когнитивные нарушения в общеклинической практике. М., 2009.Захаров В.В., Локшина А.Б. Когнитивные нарушения в общеклинической практике. М., 2009.Larrieu S, Letenneur L, Orgogozo J.M. Incidence and outcome of mild cognitive impairment in a population - based prospective cohort. Neurology 2002; 59: 1594-9.Larrieu S, Letenneur L, Orgogozo J.M. Incidence and outcome of mild cognitive impairment in a population - based prospective cohort. Neurology 2002; 59: 1594-9.Левин О.С. Диагностика и лечение деменции в клинической практике. М.: МЕДпресс-информ, 2010.Левин О.С. Диагностика и лечение деменции в клинической практике. М.: МЕДпресс-информ, 2010.Диагностика и лечение артериальной гипертензии // Системные гипертензии. 2010; 3: 5-26.Диагностика и лечение артериальной гипертензии // Системные гипертензии. 2010; 3: 5-26.Henderson A.S. Dementia. World Health Organization, Geneva 1994; p. 70.Henderson A.S. Dementia. World Health Organization, Geneva 1994; p. 70.Amaducci L, Andrea L. The epidemiology of the dementia in Europe. In: A.Culebras, J.Matias Cuiu, G.Roman: New concepts in vascular dementia. Barselona: Prous Science Publishers, 1993; p. 1927.Amaducci L, Andrea L. The epidemiology of the dementia in Europe. In: A.Culebras, J.Matias Cuiu, G.Roman: New concepts in vascular dementia. Barselona: Prous Science Publishers, 1993; p. 1927.Левин О.С., Дамулин И.В. Диффузные изменения белого вещества (лейкоареоз) и проблема сосудистой деменции. В кн.: Достижения в нейрогериатрии. Ч. 2. Под ред. Н.Н.Яхно, И.В.Дамулина. М., 1995; с.189-231.Левин О.С., Дамулин И.В. Диффузные изменения белого вещества (лейкоареоз) и проблема сосудистой деменции. В кн.: Достижения в нейрогериатрии. Ч. 2. Под ред. Н.Н.Яхно, И.В.Дамулина. М., 1995; с.189-231.Awad I.A, Masaryk T, Magdinec M. Pathogenesis of subcortical hypertense lesions on MRI of the brain. Stroke 1993; 24: 1339-46.Awad I.A, Masaryk T, Magdinec M. Pathogenesis of subcortical hypertense lesions on MRI of the brain. Stroke 1993; 24: 1339-46.Inzitari D, Marinoni M, Ginanneschi A. Pathophysiology of leucoaraiosis. In: New concepts in vascular dementia. A.Culebras, J.Matias Guiu, G.Roman (eds). Barcelona: Prous Science Publishers, 1993; p. 103-13.Inzitari D, Marinoni M, Ginanneschi A. Pathophysiology of leucoaraiosis. In: New concepts in vascular dementia. A.Culebras, J.Matias Guiu, G.Roman (eds). Barcelona: Prous Science Publishers, 1993; p. 103-13.Дамулин И.В. Сосудистая деменция. Неврол. журн. 1999; 3 (4): 411.Дамулин И.В. Сосудистая деменция. Неврол. журн. 1999; 3 (4): 411.Лурия А.Р. Высшие корковые функции человека. М.: Изд - во МГУ, 1969.Лурия А.Р. Высшие корковые функции человека. М.: Изд - во МГУ, 1969.Лурия А.Р. Основы нейропсихологии. М.: Изд - во МГУ, 1973.Лурия А.Р. Основы нейропсихологии. М.: Изд - во МГУ, 1973.Лурия.А.Р. Лобные доли и регуляция психических процессов. М.: Изд - во МГУ, 1966.Лурия.А.Р. Лобные доли и регуляция психических процессов. М.: Изд - во МГУ, 1966.Skoog I, Lernfelt B, Landahl S et al. 15-years longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-5.Skoog I, Lernfelt B, Landahl S et al. 15-years longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-5.Launer L.J, Masaki K, Petrovitch H et al. The assotiation between midlife blood pressure levels and late - life cognitive function. The Honolulu - Asia Aging Study. JAMA 1995; 274: 1846-51.Launer L.J, Masaki K, Petrovitch H et al. The assotiation between midlife blood pressure levels and late - life cognitive function. The Honolulu - Asia Aging Study. JAMA 1995; 274: 1846-51.Cacciatore F, Abete P, Ferrara N et al. The role of blood pressure in cognitive impairment in an elderly population. J Hypertens 2002; 15: 135-42.Cacciatore F, Abete P, Ferrara N et al. The role of blood pressure in cognitive impairment in an elderly population. J Hypertens 2002; 15: 135-42.Elias P.K, D’Agostino R.B, Elias M.F, Wolf P.A. Blood pressure, hypertension, and age as risk factors for poor cognitive performance. Exp Aging Res 1995; 21: 393-417.Elias P.K, D’Agostino R.B, Elias M.F, Wolf P.A. Blood pressure, hypertension, and age as risk factors for poor cognitive performance. Exp Aging Res 1995; 21: 393-417.Singh-Manoux A, Marmot M. High blood pressure was associated with cognitive function in middle - age in the Whitehall II study. J Clin Epidemiol 2005; 58: 1308-15.Singh-Manoux A, Marmot M. High blood pressure was associated with cognitive function in middle - age in the Whitehall II study. J Clin Epidemiol 2005; 58: 1308-15.Парфенов В.А., Старчина Ю.А. Когнитивные нарушения у пациентов с артериальной гипертензией и их лечение. Неврология, нейропсихиатрия, психосоматика. 2011; 1: 27-33.Парфенов В.А., Старчина Ю.А. Когнитивные нарушения у пациентов с артериальной гипертензией и их лечение. Неврология, нейропсихиатрия, психосоматика. 2011; 1: 27-33.Старчина Ю.А., Парфенов В.А., Чазова И.Е. и др. Когнитивные расстройства у пациентов с артериальной гипертензией. Журн. неврологии и психиатрии им. С.С.Корсакова 2008; 4: 39-43.Старчина Ю.А., Парфенов В.А., Чазова И.Е. и др. Когнитивные расстройства у пациентов с артериальной гипертензией. Журн. неврологии и психиатрии им. С.С.Корсакова 2008; 4: 39-43.Sharp S.I, Aarsland D, Day S et al. Hypertension is a potential risk factor for vascular dementia: systematic review. Int J Geriatr Psychiatry 2011; 26: 661-9.Sharp S.I, Aarsland D, Day S et al. Hypertension is a potential risk factor for vascular dementia: systematic review. Int J Geriatr Psychiatry 2011; 26: 661-9.Gifford K.A, Badaracco M, Liu D et al. Blood pressure and cognition among older adults: a meta - analysis. [References]. Arch Clin Neuropsychol 2013; 28: 649-64.Gifford K.A, Badaracco M, Liu D et al. Blood pressure and cognition among older adults: a meta - analysis. [References]. Arch Clin Neuropsychol 2013; 28: 649-64.Forette F, Seux M-L, Staessen J.A et al. for the Syst - Eur Investigators. The Prevention of Dementia with Antihypertensive Treatment. New evidence from the Systolic Hypertension (Syst - Eur) Study. Arch Intern Med 2002; 162 (18): 2046-52.Forette F, Seux M-L, Staessen J.A et al. for the Syst - Eur Investigators. The Prevention of Dementia with Antihypertensive Treatment. New evidence from the Systolic Hypertension (Syst - Eur) Study. Arch Intern Med 2002; 162 (18): 2046-52.Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The study on cognition and prognosis in the elderly (SCOPE). Principal results of a randomised double - blind intervention trial. J Hypertens 2003; 21: 875-86.Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The study on cognition and prognosis in the elderly (SCOPE). Principal results of a randomised double - blind intervention trial. J Hypertens 2003; 21: 875-86.PROGRESS collaborative study group. Randomised trial of perindopril based blood pressure - lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.PROGRESS collaborative study group. Randomised trial of perindopril based blood pressure - lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.Marpillat N.L, Macquin-Mavier I, Tropeano A-I et al. Antihypertensive classes, cognitive decline andincidence of dementia: a networkmeta - analysis. J Hypertens 2013, 31 (6): 1073-82.Marpillat N.L, Macquin-Mavier I, Tropeano A-I et al. Antihypertensive classes, cognitive decline andincidence of dementia: a networkmeta - analysis. J Hypertens 2013, 31 (6): 1073-82.Chiu W-C, Ho W-C, Lin M-H et al. Health Data Analysis in Taiwan (hDATa) Research Group. Angiotension receptor blockers reduce the risk of dementia. J Hypertens 2014, 32: 938-47.Chiu W-C, Ho W-C, Lin M-H et al. Health Data Analysis in Taiwan (hDATa) Research Group. Angiotension receptor blockers reduce the risk of dementia. J Hypertens 2014, 32: 938-47.Li N.C, Lee A, Whitmer R.A et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465.Li N.C, Lee A, Whitmer R.A et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465.Davies N.M, Kehoe P.G, Ben-Shlomo Y, Martin R.M. Associations of antihypertensive treatments with Alzheimer’s disease, vascular dementia, and other dementias. J Alzheimers Dis 2011; 26: 699-708.Davies N.M, Kehoe P.G, Ben-Shlomo Y, Martin R.M. Associations of antihypertensive treatments with Alzheimer’s disease, vascular dementia, and other dementias. J Alzheimers Dis 2011; 26: 699-708.Hajjar I, Brown L, Mack W.J, Chui H. Impact of Angiotensin Receptor Blockers on Alzheimer Disease Neuropathology in a Large Brain Autopsy Series. Arch Neurol 2012; 69 (12): 1632-8.Hajjar I, Brown L, Mack W.J, Chui H. Impact of Angiotensin Receptor Blockers on Alzheimer Disease Neuropathology in a Large Brain Autopsy Series. Arch Neurol 2012; 69 (12): 1632-8.Hanon O, Pequignot R. Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. J Hypertens 2006; 24 (10): 2101-7.Hanon O, Pequignot R. Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. J Hypertens 2006; 24 (10): 2101-7.Карпов Ю.А. Валсартан: центральное место в лечении кардиологического больного. Новости кардиологии. 2014; 2: 52-6.Карпов Ю.А. Валсартан: центральное место в лечении кардиологического больного. Новости кардиологии. 2014; 2: 52-6.Julius S, Kjeldsen S.E, Weber M et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363 (9426): 2022-31.Julius S, Kjeldsen S.E, Weber M et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363 (9426): 2022-31.Mc Murray J, Solomon S, Pieper K et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006; 47 (4): 726-33.Mc Murray J, Solomon S, Pieper K et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006; 47 (4): 726-33.Peters S, Götting B, Trümmel M et al. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol 2001; 13 (2): 93-7.Peters S, Götting B, Trümmel M et al. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol 2001; 13 (2): 93-7.Peters S, Trümmel M, Meyners W et al. Valsartan versus ACE inhibition after bare metal stent implantation - results of the VALVACE trial. Int J Cardiol 2005; 98 (2): 331-5.Peters S, Trümmel M, Meyners W et al. Valsartan versus ACE inhibition after bare metal stent implantation - results of the VALVACE trial. Int J Cardiol 2005; 98 (2): 331-5.Maggioni A.P, Latini R, Carson P.E et al. Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149 (3): 548-57.Maggioni A.P, Latini R, Carson P.E et al. Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149 (3): 548-57.Hara Y, Motohashi C.P, Kobayashi S. Effects of angiotensin II receptor blocker (ARB) on blood pressure and cognitive function in cerebrovascular patients with hypertension. Jpn J Stroke 2010; 32: 334-9.Hara Y, Motohashi C.P, Kobayashi S. Effects of angiotensin II receptor blocker (ARB) on blood pressure and cognitive function in cerebrovascular patients with hypertension. Jpn J Stroke 2010; 32: 334-9.Katada E, Uematsu N, Takuma Y, Matsukawa N. Comparison of effects of valsartan and amlodipine on cognitive functions and auditory p300 event - related potentials in elderly hypertensive patients. Clin Neuropharmacol 2014; 37 (5): 129-32. DOI: 10.1097/WNF.0000000000000042.Katada E, Uematsu N, Takuma Y, Matsukawa N. Comparison of effects of valsartan and amlodipine on cognitive functions and auditory p300 event - related potentials in elderly hypertensive patients. Clin Neuropharmacol 2014; 37 (5): 129-32. DOI: 10.1097/WNF.0000000000000042.Fogari R, Mugellini A, Zoppi A et al. Effects of Valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 2004; 59 (12): 863-8.Fogari R, Mugellini A, Zoppi A et al. Effects of Valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 2004; 59 (12): 863-8.Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010; 7 (3): 5-26.Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010; 7 (3): 5-26.Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-357.Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-357.O’Brien E, Parati G, Stergiou G et al. On behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. Guidelines European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring. J Hypertens 2013; 31: 1731-68.O’Brien E, Parati G, Stergiou G et al. On behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. Guidelines European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring. J Hypertens 2013; 31: 1731-68.Wechsler D. Manual for the Wechsler Adult Intelligence Scale. New York: Psychological Corporation, 1955.Wechsler D. Manual for the Wechsler Adult Intelligence Scale. New York: Psychological Corporation, 1955.Дружинин В.Н. Психология общих способностей. СПб.: Питер, 2007; с. 368.Дружинин В.Н. Психология общих способностей. СПб.: Питер, 2007; с. 368.Лурия А.Р. Основы нейропсихологии. Учеб. пособ. для студ. высш. учеб. заведений. М.: Академия, 2003; с. 384.Лурия А.Р. Основы нейропсихологии. Учеб. пособ. для студ. высш. учеб. заведений. М.: Академия, 2003; с. 384.Bames J.M, Barns N.M, Costall B et al. Angiotensin II ingibits the resease of (3H)acetylcholine from rat entorhinal cortex in vivo. Brain Res 1989; 492: 136-43.Bames J.M, Barns N.M, Costall B et al. Angiotensin II ingibits the resease of (3H)acetylcholine from rat entorhinal cortex in vivo. Brain Res 1989; 492: 136-43.Okuyama S, Sakagawa T, Inagami T. Role of angiotensin II type 2 receptor in the mouse central nervous system. Jpn J Pharmacol 1999; 81: 259-63.Okuyama S, Sakagawa T, Inagami T. Role of angiotensin II type 2 receptor in the mouse central nervous system. Jpn J Pharmacol 1999; 81: 259-63.Wright J.W, Stubley L.A, Pederson E.S et al. Contributions of the brain angiotensin `IV-AT4 receptor subtype system to spatial learning. J Neurosci 1999; 19: 3952-61.Wright J.W, Stubley L.A, Pederson E.S et al. Contributions of the brain angiotensin `IV-AT4 receptor subtype system to spatial learning. J Neurosci 1999; 19: 3952-61.Villapol S, Saavedra J.M. Neuroprotective effects of angiotensin receptor blockers. Am J Hypertens 2015; 28 (3): 289-99.Villapol S, Saavedra J.M. Neuroprotective effects of angiotensin receptor blockers. Am J Hypertens 2015; 28 (3): 289-99.Saavedra J.M. Brain and pituitary angiotensin. Endocr Rev 1992; 13: 329-80.Saavedra J.M. Brain and pituitary angiotensin. Endocr Rev 1992; 13: 329-80.Zhou J, Pavel J, Macova M et al. AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Stroke 2006; 37: 1271-6.Zhou J, Pavel J, Macova M et al. AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Stroke 2006; 37: 1271-6.Shigematsu K, Saavedra J.M, Plunkett L.M et al. Angiotensin II binding sites in the anteroventral - third ventricle (AV3V) area and related structures of the rat brain. Neurosci Lett 1986; 67: 37-41.Shigematsu K, Saavedra J.M, Plunkett L.M et al. Angiotensin II binding sites in the anteroventral - third ventricle (AV3V) area and related structures of the rat brain. Neurosci Lett 1986; 67: 37-41.Duvernoy H.M, Risold P-Y. The circumventricular organs: An atlas of comparative anatomy and vascularization. Brain Res Rev 2007; 56: 119-47. DOI:10.1016/j.brainresrev.2007.06.002.Duvernoy H.M, Risold P-Y. The circumventricular organs: An atlas of comparative anatomy and vascularization. Brain Res Rev 2007; 56: 119-47. DOI:10.1016/j.brainresrev.2007.06.002.Min L.J, Mogi M, Shudou M et al. Peroxisome proliferator - activated receptor-g activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood - brain barrier impairment and cognitive decline in type 2 diabetic mice. Hypertension 2012; 59: 1079-88.Min L.J, Mogi M, Shudou M et al. Peroxisome proliferator - activated receptor-g activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood - brain barrier impairment and cognitive decline in type 2 diabetic mice. Hypertension 2012; 59: 1079-88.Pelisch N, Hosomi N, Ueno M et al. Blockade of AT1 receptors protects the blood - brain barrier and improves cognition in Dahl salt - sensitive hypertensive rats. Am J Hypertens 2011; 24: 362-8.Pelisch N, Hosomi N, Ueno M et al. Blockade of AT1 receptors protects the blood - brain barrier and improves cognition in Dahl salt - sensitive hypertensive rats. Am J Hypertens 2011; 24: 362-8.Benicky J, Sánchez-Lemus E, Honda M et al. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology 2011; 36 (8): 57-70.Benicky J, Sánchez-Lemus E, Honda M et al. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology 2011; 36 (8): 57-70.Benicky J, Sánchez-Lemus E, Pavel J, Saavedra J.M. Anti - inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Mol Neurobiol 2009; 29: 781-92.Benicky J, Sánchez-Lemus E, Pavel J, Saavedra J.M. Anti - inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Mol Neurobiol 2009; 29: 781-92.Nishimura Y, Ito T, Hoe K, Saavedra J.M. Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors. Brain Res 2000; 871: 29-38.Nishimura Y, Ito T, Hoe K, Saavedra J.M. Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors. Brain Res 2000; 871: 29-38.Seltzer A, Bregonzio C, Armando I et al. Oral administration of an AT1 receptor antagonist prevents the central effects of angiotensin II in spontaneously hypertensive rats. Brain Res 2004; 1028: 9-18.Seltzer A, Bregonzio C, Armando I et al. Oral administration of an AT1 receptor antagonist prevents the central effects of angiotensin II in spontaneously hypertensive rats. Brain Res 2004; 1028: 9-18.Saavedra J.M. Angiotensin II AT(1)-receptor blockers ameliorate inflammatory stress: a beneficial effect for the treatment of brain disorders. Cell Mol Neurobiol 2012; 32: 667-81.Saavedra J.M. Angiotensin II AT(1)-receptor blockers ameliorate inflammatory stress: a beneficial effect for the treatment of brain disorders. Cell Mol Neurobiol 2012; 32: 667-81.Bader M. Tissue renin - angiotensin - aldosterone systems: Targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 2010; 50: 439-65.Bader M. Tissue renin - angiotensin - aldosterone systems: Targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 2010; 50: 439-65.Nap A, Balt J.C, Mathy M.J, Van Zwieten P.A. AT(1)-receptor blockade and sympathetic neurotransmission in cardiovascular disease. Auton Autacoid Pharmacol 2003; 23: 285-96.Nap A, Balt J.C, Mathy M.J, Van Zwieten P.A. AT(1)-receptor blockade and sympathetic neurotransmission in cardiovascular disease. Auton Autacoid Pharmacol 2003; 23: 285-96.Tsutsumi K, Saavedra J.M. Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Physiol 1991; 261: 209-16.Tsutsumi K, Saavedra J.M. Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Physiol 1991; 261: 209-16.Quan N, Banks W.A. Brain - immune communication pathways. Brain Behav Immun 2007; 21: 727-35.Quan N, Banks W.A. Brain - immune communication pathways. Brain Behav Immun 2007; 21: 727-35.Jaggi A.S, Singh N. Exploring the potential of telmisartan in chronic constriction injury - induced neuropathic pain in rats. Eur J Pharmacol 2011; 667: 215-21.Jaggi A.S, Singh N. Exploring the potential of telmisartan in chronic constriction injury - induced neuropathic pain in rats. Eur J Pharmacol 2011; 667: 215-21.Wang J, Ho L, Chen L et al. Valsartan lowers brain b-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117 (11): 3393-402.Wang J, Ho L, Chen L et al. Valsartan lowers brain b-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117 (11): 3393-402.

The authors declare that there are no conflicts of interest present.